Fludrocortisone (DrugBank: Fludrocortisone)
3 diseases| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 6 | パーキンソン病 | 2 |
| 17 | 多系統萎縮症 | 1 |
| 81 | 先天性副腎皮質酵素欠損症 | 2 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01993680 (ClinicalTrials.gov) | June 2012 | 27/4/2012 | Orthostatic Dysregulation and Associated Gastrointestinal Dysfunction in Parkinson's Disease -Treatment | A Monocentric Randomized, Controlled, Double Blind, Crossover Phase II Trial to Show Non-inferiority of the Effect of Pyridostigmine Bromide vs. Fludrocortisone on Symptoms of Autonomic Dysregulation in Parkinson's Disease | Autonomic Disturbances in Parkinson's Disease | Drug: Pyridostigmine bromide;Drug: fludrocortisone | Christian Baumann | NULL | Completed | 50 Years | 80 Years | All | 18 | Phase 2 | Switzerland |
| 2 | NCT00103597 (ClinicalTrials.gov) | January 2005 | 11/2/2005 | Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System Atrophy | Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System Atrophy | Parkinson's Disease;Multiple System Atrophy;Orthostatic Hypotension | Drug: Fludrocortisone;Drug: Domperidone;Behavioral: Conservative Measures for Orthostatic Hypotension | Royal Brisbane and Women's Hospital | NULL | Completed | 40 Years | 95 Years | Both | 50 | Phase 1 | Australia |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00103597 (ClinicalTrials.gov) | January 2005 | 11/2/2005 | Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System Atrophy | Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System Atrophy | Parkinson's Disease;Multiple System Atrophy;Orthostatic Hypotension | Drug: Fludrocortisone;Drug: Domperidone;Behavioral: Conservative Measures for Orthostatic Hypotension | Royal Brisbane and Women's Hospital | NULL | Completed | 40 Years | 95 Years | Both | 50 | Phase 1 | Australia |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03548246 (ClinicalTrials.gov) | January 2022 | 24/4/2015 | Androgen Reduction in Congenital Adrenal Hyperplasia | A Phase 1-2 Multi-Center Study to Assess the Efficacy and Safety of Abiraterone Acetate as Adjunctive Therapy in Pre-Pubescent Children With Classic 21-Hydroxylase Deficiency | Congenital Adrenal Hyperplasia | Drug: Abiraterone acetate;Drug: Placebo;Drug: Hydrocortisone;Drug: Fludrocortisone | University of Texas Southwestern Medical Center | National Institutes of Health Clinical Center (CC);University of Michigan;Children's Hospital Los Angeles;Feinstein Institute for Medical Research | Not yet recruiting | 2 Years | 9 Years | All | 54 | Phase 2 | United States |
| 2 | NCT00001521 (ClinicalTrials.gov) | June 8, 1995 | 3/11/1999 | Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia | An Open, Randomized, Long-Term Clinical Trial of Flutamide, Testolactone, and Reduced Hydrocortisone Dose vs. Conventional Treatment of Children With Congenital Adrenal Hyperplasia | Congenital Adrenal Hyperplasia (CAH) | Drug: Flutamide;Drug: Letrozole;Drug: Hydrocortisone;Drug: Fludrocortisone | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | NULL | Active, not recruiting | 2 Years | 18 Years | All | 62 | Phase 2 | United States |